Pay in 4 interest-free payments of $5.67 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
As the availability of compounded semaglutide changes, we are actively working to expand treatment options for patients in an affordable, sustainable way
1 Beyond diabetes and obesity Cardiovascular disease In March 2024, the US Food and Drug Administration (FDA) approved Wegovy (semaglutide) for adults with cardiovascular disease (CVD) and either obesity and overweight to reduce the risk of cardiovascular death, heart attack, and stroke
Herbal remedies may support metabolism but rarely cause significant breast size reduction
Though considered rare, some people have reported anaphylactic responses
Staying hydrated, eating smaller meals, and taking your injection at the same time each week help minimize adjustment symptoms
These reports suggest that hot flashes may be more common in certain individuals, particularly those who are sensitive to changes in body temperature or who have a history of hot flashes
